TOXICOLOGICAL PROFILE FOR 1,2-DIBROMOETHANE

Agency for Toxic Substances and Disease Registry
U.S. Public Health Service

July 1992

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Resister on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

(A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described, Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

William L. Roper

William L. Roper, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTENTS

FOREWORD iii

LIST OF FIGURES ix

LIST OF TABLES xi

1. PUBLIC HEALTH STATEMENT 1
   1.1 WHAT IS 1,2-DIBROMOETHANE? 1
   1.2 HOW MIGHT I BE EXPOSED TO 1,2-DIBROMOETHANE? 2
   1.3 HOW CAN 1,2-DIBROMOETHANE ENTER AND LEAVE MY BODY? 2
   1.4 HOW CAN 1,2-DIBROMOETHANE AFFECT MY HEALTH? 3
   1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,2-DIBROMOETHANE? 3
   1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? 4
   1.7 WHERE CAN I GET MORE INFORMATION? 4

2. HEALTH EFFECTS 5
   2.1 INTRODUCTION 5
   2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 5
      2.2.1 Inhalation Exposure 6
         2.2.1.1 Death 6
         2.2.1.2 Systemic Effects 15
         2.2.1.3 Immunological Effects 19
         2.2.1.4 Neurological Effects 20
         2.2.1.5 Developmental Effects 20
         2.2.1.6 Reproductive Effects 21
         2.2.1.7 Genotoxic Effects 23
         2.2.1.8 Cancer 23
      2.2.2 Oral Exposure 26
         2.2.2.1 Death 26
         2.2.2.2 Systemic Effects 31
         2.2.2.3 Immunological Effects 33
         2.2.2.4 Neurological Effects 33
         2.2.2.5 Developmental Effects 33
         2.2.2.6 Reproductive Effects 33
         2.2.2.7 Genotoxic Effects 34
         2.2.2.8 Cancer 35
      2.2.3 Dermal Exposure 37
         2.2.3.1 Death 37
         2.2.3.2 Systemic Effects 37
         2.2.3.3 Immunological Effects 40
         2.2.3.4 Neurological Effects 40
         2.2.3.5 Developmental Effects 41
         2.2.3.6 Reproductive Effects 41
         2.2.3.7 Genotoxic Effects 41
         2.2.3.8 Cancer 41

2.3 TOXICOKINETICS 42
2.3.1 Absorption 42
2.3.1.1 Inhalation Exposure 42
2.3.1.2 Oral Exposure 42
2.3.1.3 Dermal Exposure 42
2.3.2 Distribution 43
2.3.2.1 Inhalation Exposure 43
2.3.2.2 Oral Exposure 43
2.3.2.3 Dermal Exposure 43
2.3.2.4 Other Routes of Exposure 45
2.3.3 Metabolism 45
2.3.4 Excretion 50
2.3.4.1 Inhalation Exposure 50
2.3.4.2 Oral Exposure 51
2.3.4.3 Dermal Exposure 51
2.3.4.4 Other Routes of Exposure 51
2.4 RELEVANCE TO PUBLIC HEALTH 51
2.5 BIOMARKERS OF EXPOSURE AND EFFECT 63
2.5.1 Biomarkers Used to Identify and/or Quantify Exposure to 1,2-Dibromoethane 64
2.5.2 Biomarkers Used to Characterize Effects Caused by 1,2-Dibromoethane 65
2.6 INTERACTIONS WITH OTHER CHEMICALS 66
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 67
2.8 MITIGATION OF EFFECTS 67
2.9 ADEQUACY OF THE DATABASE 68
2.9.1 Existing Information on Health Effects of 1,2-Dibromoethane 69
2.9.2 Data Needs 71
2.9.3 On-going Studies 76

3. CHEMICAL AND PHYSICAL INFORMATION 77
3.1 CHEMICAL IDENTITY 77
3.2 PHYSICAL AND CHEMICAL PROPERTIES 77

4. PRODUCTION, IMPORT, USE, AND DISPOSAL 81
4.1 PRODUCTION 81
4.2 IMPORT/EXPORT 81
4.3 USE 81
4.4 DISPOSAL 84

5. POTENTIAL FOR HUMAN EXPOSURE 85
5.1 OVERVIEW 85
5.2 RELEASES TO THE ENVIRONMENT 85
5.2.1 Air 90
5.2.2 Water 90
5.2.3 Soil 90
5.3 ENVIRONMENTAL FATE 91
5.3.1 Transport and Partitioning 91
5.3.2 Transformation and Degradation 91
5.3.2.1 Air 91

5.3.2.2 Water 91
5.3.2.3 Soil 92
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 92
5.4.1 Air 92
5.4.2 Water 93
5.4.3 Soil 94
5.4.4 Other Environmental Media 94
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 94
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 95
5.7 ADEQUACY OF THE DATABASE 95
5.7.1 Data Needs 96
5.7.2 On-going Studies 98

6. ANALYTICAL METHODS 99
6.1 BIOLOGICAL MATERIALS 99
6.2 ENVIRONMENTAL SAMPLES 99
6.3 ADEQUACY OF THE DATABASE 104
6.3.1 Data Needs 104
6.3.2 On-going Studies 105

7. REGULATIONS AND ADVISORIES 107

8. REFERENCES 111

9. GLOSSARY 145

APPENDICES

A. USER'S GUIDE A-1

B. ACRONYMS, ABBREVIATIONS, AND SYMBOLS B-1

C. PEER REVIEW C-1

LIST OF FIGURES

2-1 Levels of Significant Exposure to 1,2-Dibromoethane - Inhalation . . 12

2-2 Levels of Significant Exposure to 1,2-Dibromoethane - Oral 30

2-3 Proposed Metabolic Pathways for 1,2-Dibromoethane 48

2-4 Existing Information on Health Effects of 1,2-Dibromoethane 70

5-1 Frequency of NPL Sites with 1,2-Dibromoethane Contamination 89

LIST OF TABLES

2-1 Levels of Significant Exposure to 1,2-Dibromoethane - Inhalation . . 7

2-2 Levels of Significant Exposure to 1,2-Dibromoethane - Oral 27

2-3 Levels of Significant Exposure to 1,2-Dibromoethane - Dermal 38

2-4 Distribution of ^{14}C in Selected Tissues and Body Fluids of Male Rats 24 and 48 Hours After a Single Oral Dose of 15 mg/kg [U-^{14}C]-1,2-Dibromoethane 44

2-5 Distribution of 1,2-Dibromoethane in Mice 46

2-6 Percentage of Administered ^{14}C in Selected Tissues and Body Fluids of Male Guinea Pigs at Various Time Intervals Following Intraperitoneal Administration of 30 mg/kg of ^{14}C-1,2-Dibromoethane . . . 47

2-7 Genotoxicity of 1,2-Dibromoethane In Vivo 59

2-8 Genotoxicity of 1,2-Dibromoethane In Vitro 60

3-1 Chemical Identity of 1,2-Dibromoethane 78

3-2 Physical and Chemical Properties of 1,2-Dibromoethane 80

4-1 Facilities That Manufacture or Process 1,2-Dibromoethane 82

5-1 Releases to the Environmental from Facilities That Manufacture or Process 1,2-Dibromoethane 86

6-1 Analytical Methods for Determining 1,2-Dibromoethane in Biological Materials 100

6-2 Analytical Methods for Determining 1,2-Dibromoethane in Environmental Samples 102

7-1 Regulations and Guidelines Applicable to 1,2-Dibromoethane 108